Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05328973 · ClinicalTrials.gov registry record · Phase 2
Intraoperative Aromatherapy Versus Placebo for Port-a-Cath Placement Under Monitored Anesthesia Care. A Randomized Controlled Trial
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT05328973: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT05328973 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 70 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05328973, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This is a prospective, controlled, randomized trial. Primary objective is to compare the time to readiness for discharge (minutes) from Post-Anesthesia Care Unit (PACU) after Port-a-Cath placement surgery between patients who are randomized to receive intraoperative aromatherapy versus placebo. 70 Eligible subjects will be identified from within the patient population of the study site. There will be no advertisements for study subjects.
Interventions
- OTHER ELEQUIL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2022-05-18 |
| Est. Completion | 2024-01-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05328973
The ClinicalTrials.gov registry entry for NCT05328973 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ELEQUIL is the first listed.
NCT05328973 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05328973 about?
NCT05328973 is a clinical study titled "Intraoperative Aromatherapy Versus Placebo for Port-a-Cath Placement Under Monitored Anesthesia Care. A Randomized Controlled Trial". This is a prospective, controlled, randomized trial. Primary objective is to compare the time to readiness for discharge (minutes) from Post-Anesthesia Care Unit (PACU) after Port-a-Cath placement surgery between patients who are randomized to receive intraoperative aromatherapy versus placebo. 70 E...
What is the current status of trial NCT05328973?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2022-05-18. Estimated completion is 2024-01-16.
What interventions are being tested in trial NCT05328973?
The interventions under investigation include: ELEQUIL (OTHER).
Who is sponsoring clinical trial NCT05328973?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.